Systemic mastocytosis: current landscape, novel agents and COVID-19
Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…
Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…
Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, provides a comprehensive overview of the current key trials in the…
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, summarizes the current standard of care (SoC) for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).…
The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology…
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the potential for using measurable residual disease (MRD) status to…
Maël Heiblig, MD, Hôpital Lyon Sud, Lyon, France, discusses the current treatment approaches for patients with VEXAS syndrome, which include controlling inflammation, controlling the clone,…
Read about the FDA approval of fidanacogene elaparvovec, a one-time gene therapy, for adults with hemophilia B.
Tune in to this week’s VJHemOnc podcast to learn more about current & emerging treatment options for acute & chronic GvHD, as well as the…
James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, introduces a system for the risk…